312 related articles for article (PubMed ID: 27422935)
1. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
[TBL] [Abstract][Full Text] [Related]
2. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
3.
Infante JR; Cabrera J; Rayo JI; Cruz C; Serrano J; Moreno M; Martínez A; Jiménez P; Cobo A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):353-359. PubMed ID: 32605894
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
6. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
10. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
12. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
14. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
[TBL] [Abstract][Full Text] [Related]
16. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
Li Y; Zschaeck S; Lin Q; Chen S; Chen L; Wu H
Radiat Oncol; 2019 Feb; 14(1):35. PubMed ID: 30782182
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
18. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
[TBL] [Abstract][Full Text] [Related]
19. Metabolic tumor volume derived from
Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
